Physician profile
Tracy Barefield
NPI 1033159520
$1,094.43
in general payments reported to CMS, 2019-2025
20 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $287 · 2021: $163 · 2022: $172 · 2023: $162 · 2024: $99.69 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.41 | 2019-2023 | |
| Lilly USA, LLC | $183.52 | 2020-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $142.46 | 2022-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $131.42 | 2019-2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $93.32 | 2021-2024 | Farxiga, Airsupra |
| Abbvie INC. | $50.92 | 2023 | Vraylar |
| Idorsia Pharmaceuticals US INC | $47.44 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $31.58 | 2025 | |
| Boston Scientific Corporation | $29.58 | 2019 | |
| Alkermes, INC. | $22.51 | 2022 | |
| Neos Therapeutics, LP | $20.52 | 2020 | |
| Merck Sharp & Dohme LLC | $19.62 | 2025 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.84 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.40 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $16.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.75 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2022 | |
| Nabriva Therapeutics, Plc | $12.60 | 2021 | |
| Daiichi Sankyo INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Barefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.